Cardiorenovascular effects of urotensin II and the relevance of the UT receptor

Peptides

Volumn 29, Issue 5, 2008, Pages 743-763

  Tölle, Markus ^a   van der Giet, Markus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Blood pressure; Cardiovascular disease; Renal disease; Urotensin; Urotensin receptor

Indexed keywords

ATROPINE; BURIMAMIDE; G PROTEIN COUPLED RECEPTOR; HYDROQUINONE; INDOMETACIN; N (6 AMINOHEXYL) 5 CHLORO 1 NAPHTHALENESULFONAMIDE; NITRENDIPINE; PALOSURAN; PHENTOLAMINE; PROPRANOLOL; SOMATOSTATIN; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; UROTENSIN II; UROTENSIN II RECEPTOR ANTAGONIST; VERAPAMIL;

ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CELL PROLIFERATION; CLINICAL TRIAL; DRUG MECHANISM; HEART FAILURE; HEART MUSCLE CELL; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; METABOLIC DISORDER; MUSCLE CONTRACTILITY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASODILATATION;

ANIMALS; CARDIOVASCULAR SYSTEM; HEART DISEASES; HUMANS; KIDNEY; KIDNEY DISEASES; MYOCARDIUM; QUINOLINES; RECEPTORS, G-PROTEIN-COUPLED; TISSUE DISTRIBUTION; UREA; UROTENSINS; VASOCONSTRICTION; VASODILATION;

EID: 42049105098     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2007.08.029     Document Type: Article

References (138)

1. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-266.
2. Affolter J.T., Newby D.E., Wilkinson I.B., Winter M.J., Balment R.J., and Webb D.J. No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. Br J Clin Pharmacol 54 (2002) 617-621
3. Aiyar N., Johns D.G., Ao Z., Disa J., Behm D.J., Foley J.J., et al. Cloning and pharmacological characterization of the cat urotensin-II receptor (UT). Biochem Pharmacol 69 (2005) 1069-1079
4. Amento E.P., Ehsani N., Palmer H., and Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 11 (1991) 1223-1230
5. Ames R.S., Sarau H.M., Chambers J.K., Willette R.N., Aiyar N.V., Romanic A.M., et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401 (1999) 282-286
6. Balat O., Aksoy F., Kutlar I., Ugur M.G., Iyikosker H., Balat A., et al. Increased plasma levels of urotensin-II in preeclampsia-eclampsia: a new mediator in pathogenesis?. Eur J Obstet Gynecol Reprod Biol 120 (2005) 33-38
7. Balment R.J., Song W., and Ashton N. Urotensin II: ancient hormone with new functions in vertebrate body fluid regulation. Ann NY Acad Sci 1040 (2005) 66-73
8. Behm D.J., Ao Z., Camarda V., Aiyar N.V., Johns D.G., and Douglas S.A. Inhibitory effects of putative peptidic urotensin-II receptor antagonists on urotensin-II-induced contraction of cat isolated respiratory smooth muscle. Eur J Pharmacol 516 (2005) 276-281
9. Behm D.J., Doe C.P., Johns D.G., Maniscalco K., Stankus G.P., Wibberley A., et al. Urotensin-II: a novel systemic hypertensive factor in the cat. Naunyn Schmiedebergs Arch Pharmacol 369 (2004) 274-280
10. Behm D.J., Harrison S.M., Ao Z., Maniscalco K., Pickering S.J., Grau E.V., et al. Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice. Br J Pharmacol 139 (2003) 464-472
11. Behm D.J., Stankus G., Doe C.P., Willette R.N., Sarau H.M., Foley J.J., et al. The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems. Br J Pharmacol 148 (2006) 173-190
12. Bohm F., and Pernow J. Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 135 (2002) 25-27
13. Bond H., Winter M.J., Warne J.M., McCrohan C.R., and Balment R.J. Plasma concentrations of arginine vasotocin and urotensin II are reduced following transfer of the euryhaline floander (Platichthys flesus) from seawater to fresh water. Gen Comp Endocrinol 125 (2002) 113-120
14. Bottrill F.E., Douglas S.A., Hiley C.R., and White R. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 130 (2000) 1865-1870
15. Bousette N., Hu F., Ohlstein E.H., Dhanak D., Douglas S.A., and Giaid A. Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. J Mol Cell Cardiol 41 (2006) 285-295
16. Bousette N., Patel L., Douglas S.A., Ohlstein E.H., and Giaid A. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 176 (2004) 117-123
17. Bousette N., Pottinger J., Ramli W., Ohlstein E.H., Dhanak D., Douglas S.A., et al. Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease. Peptides 27 (2006) 2919-2926
18. Camarda V., Rizzi A., Calo G., Gendron G., Perron S.I., Kostenis E., et al. Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. Naunyn Schmiedebergs Arch Pharmacol 365 (2002) 141-149
19. Charles C.J., Rademaker M.T., Richards A.M., and Yandle T.G. Urotensin II: evidence for cardiac, hepatic and renal production. Peptides 26 (2005) 2211-2214
20. Chen Y., Zhao M., Liu X., Yao W., Yang J., Zhang Z., et al. Urotensin II receptor in the rat airway smooth muscle and its effect on the rat airway smooth muscle cells proliferation. Chin Med Sci J 16 (2001) 231-235
21. Chen Y., Zhao M., and Xia C. [Effect of urotensin II on the airway smooth muscle cell proliferation and its mechanism]. Zhonghua Yi Xue Za Zhi 80 (2000) 928-930
22. Chen Y.H., Zhao M.W., Yao W.Z., Pang Y.Z., and Tang C.S. The signal transduction pathway in the proliferation of airway smooth muscle cells induced by urotensin II. Chin Med J (Engl) 117 (2004) 37-41
23. Cheung B.M., Leung R., Man Y.B., and Wong L.Y. Plasma concentration of urotensin II is raised in hypertension. J Hypertens 22 (2004) 1341-1344
24. Claing A., Laporte S.A., Caron M.G., and Lefkowitz R.J. Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. Prog Neurobiol 66 (2002) 61-79
25. Clozel M., Hess P., Qiu C., Ding S.S., and Rey M. The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. J Pharmacol Exp Ther 316 (2006) 1115-1121
26. Conlon J.M. "Liberation" of urotensin II from the teleost urophysis: an historical overview. Peptides (2007)
27. Conlon J.M., Arnold-Reed D., and Balment R.J. Post-translational processing of prepro-urotensin II. FEBS Lett 266 (1990) 37-40
28. Conlon J.M., Yano K., Waugh D., and Hazon N. Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates. J Exp Zool 275 (1996) 226-238
29. Coulouarn Y., Lihrmann I., Jegou S., Anouar Y., Tostivint H., Beauvillain J.C., et al. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA 95 (1998) 15803-15808
30. Disa J., Floyd L.E., Edwards R.M., Douglas S.A., and Aiyar N.V. Identification and characterization of binding sites for human urotensin-II in Sprague-Dawley rat renal medulla using quantitative receptor autoradiography. Peptides 27 (2006) 1532-1537
31. Douglas S.A. Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'?. Curr Opin Pharmacol 3 (2003) 159-167
32. Douglas S.A., Ashton D.J., Sauermelch C.F., Coatney R.W., Ohlstein D.H., Ruffolo M.R., et al. Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate. J Cardiovasc Pharmacol 36 (2000) S163-S166
33. Douglas S.A., Dhanak D., and Johns D.G. From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci 25 (2004) 76-85
34. Douglas S.A., and Ohlstein E.H. Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med 10 (2000) 229-237
35. Douglas S.A., Sulpizio A.C., Piercy V., Sarau H.M., Ames R.S., Aiyar N.V., et al. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 131 (2000) 1262-1274
36. Douglas S.A., Tayara L., Ohlstein E.H., Halawa N., and Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 359 (2002) 1990-1997
37. Dschietzig T., Bartsch C., Pregla R., Zurbrugg H.R., Armbruster F.P., Richter C., et al. Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure. Regul Pept 110 (2002) 33-38
38. Elshourbagy N.A., Douglas S.A., Shabon U., Harrison S., Duddy G., Sechler J.L., et al. Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br J Pharmacol 136 (2002) 9-22
39. Foley R.N., Parfrey P.S., and Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 (1998) S112-S119
40. Gardiner S.M., March J.E., Kemp P.A., Davenport A.P., and Bennett T. Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats. Br J Pharmacol 132 (2001) 1625-1629
41. Gardiner S.M., March J.E., Kemp P.A., Maguire J.J., Kuc R.E., Davenport A.P., et al. Regional heterogeneity in the hemodynamic responses to urotensin II infusion in relation to UT receptor localisation. Br J Pharmacol 147 (2006) 612-621
42. Gendron G., Gobeil Jr. F., Belanger S., Gagnon S., Regoli D., and D'Orleans-Juste P. Urotensin II-induced hypotensive responses in Wistar-Kyoto (Wky) and spontaneously hypertensive (Shr) rats. Peptides 26 (2005) 1468-1474
43. Gibson A. Complex effects of Gillichthys urotensin II on rat aortic strips. Br J Pharmacol 91 (1987) 205-212
44. Gibson A., Conyers S., and Bern H.A. The influence of urotensin II on calcium flux in rat aorta. J Pharm Pharmacol 40 (1988) 893-895
45. Gibson A., Wallace P., and Bern H.A. Cardiovascular effects of urotensin II in anesthetized and pithed rats. Gen Comp Endocrinol 64 (1986) 435-439
46. Giebing G., Tolle M., Jurgensen J., Eichhorst J., Furkert J., Beyermann M., et al. Arrestin-independent internalization and recycling of the urotensin receptor contribute to long-lasting urotensin II-mediated vasoconstriction. Circ Res 97 (2005) 707-715
47. Gray G.A., Jones M.R., and Sharif I. Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition. Life Sci 69 (2001) 175-180
48. Gruson D., Rousseau M.F., Ahn S.A., van Linden F., and Ketelslegers J.M. Circulating urotensin II levels in moderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers. Peptides 27 (2006) 1527-1531
49. Hassan G.S., Chouiali F., Saito T., Hu F., Douglas S.A., Ao Z., et al. Effect of human urotensin-II infusion on hemodynamics and cardiac function. Can J Physiol Pharmacol 81 (2003) 125-128
50. Hassan G.S., Douglas S.A., Ohlstein E.H., and Giaid A. Expression of urotensin-II in human coronary atherosclerosis. Peptides 26 (2005) 2464-2472
51. Hay D.W., Luttmann M.A., and Douglas S.A. Human urotensin-II is a potent spasmogen of primate airway smooth muscle. Br J Pharmacol 131 (2000) 10-12
52. Hazon N., Bjenning C., and Conlon J.M. Cardiovascular actions of dogfish urotensin II in the dogfish Scyliorhinus canicula. Am J Physiol 265 (1993) R573-R576
53. Heller J., Schepke M., Neef M., Woitas R., Rabe C., and Sauerbruch T. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. J Hepatol 37 (2002) 767-772
54. Heringlake M., Kox T., Uzun O., Will B., Bahlmann L., Klaus S., et al. The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease. Regul Pept 121 (2004) 129-136
55. Hillier C., Berry C., Petrie M.C., O'Dwyer P.J., Hamilton C., Brown A., et al. Effects of urotensin II in human arteries and veins of varying caliber. Circulation 103 (2001) 1378-1381
56. Hood S.G., Watson A.M., and May C.N. Cardiac actions of central but not peripheral urotensin II are prevented by beta-adrenoceptor blockade. Peptides 26 (2005) 1248-1256
57. Horie S., Yasuda S., Tsurumaki Y., Someya A., Saito T., Okuma Y., et al. Contraction of isolated guinea-pig ileum by urotensin II via activation of ganglionic cholinergic neurons and acetylcholine release. Neuropharmacology 45 (2003) 1019-1027
58. Ishihata A., Ogaki T., Aita T., and Katano Y. Role of prostaglandins in urotensin II-induced vasodilatation in the coronary arteries of aged rats. Eur J Pharmacol 523 (2005) 119-126
59. Itoh H., Itoh Y., Rivier J., and Lederis K. Contraction of major artery segments of rat by fish neuropeptide urotensin II. Am J Physiol 252 (1987) R361-R366
60. Itoh H., McMaster D., and Lederis K. Functional receptors for fish neuropeptide urotensin II in major rat arteries. Eur J Pharmacol 149 (1988) 61-66
61. Johns D.G., Ao Z., Naselsky D., Herold C.L., Maniscalco K., Sarov-Blat L., et al. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol 370 (2004) 238-250
62. Katano Y., Ishihata A., Aita T., Ogaki T., and Horie T. Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries. Eur J Pharmacol 402 (2000) R5-R7
63. Khan S.Q., Bhandari S.S., Quinn P., Davies J.E., and Ng L.L. Urotensin II is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans. Int J Cardiol 117 (2007) 323-328
64. Koomans H.A., Blankestijn P.J., and Joles J.A. Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol 15 (2004) 524-537
65. Labarrere P., Chatenet D., Leprince J., Marionneau C., Loirand G., Tonon M.C., et al. Structure-activity relationships of human urotensin II and related analogues on rat aortic ring contraction. J Enzyme Inhib Med Chem 18 (2003) 77-88
66. Lacza Z., and Busija D.W. Urotensin-II is a nitric oxide-dependent vasodilator in the pial arteries of the newborn pig. Life Sci 78 (2006) 2763-2776
67. Langham R.G., Kelly D.J., Gow R.M., Zhang Y., Dowling J.K., Thomson N.M., et al. Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. Am J Kidney Dis 44 (2004) 826-831
68. Lapp H., Boerrigter G., Costello-Boerrigter L.C., Jaekel K., Scheffold T., Krakau I., et al. Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. Int J Cardiol 94 (2004) 93-97
69. Le Mevel J.C., Olson K.R., Conklin D., Waugh D., Smith D.D., Vaudry H., et al. Cardiovascular actions of trout urotensin II in the conscious trout, Oncorhynchus mykiss. Am J Physiol 271 (1996) R1335-R1343
70. Li L., Yuan W.J., and Su D.F. Effects of rat urotensin II on coronary flow and myocardial eNOS protein expression in isolated rat heart. Acta Pharmacol Sin 25 (2004) 1444-1449
71. Lim M., Honisett S., Sparkes C.D., Komesaroff P., Kompa A., and Krum H. Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation 109 (2004) 1212-1214
72. Liu Q., Pong S.S., Zeng Z., Zhang Q., Howard A.D., Williams Jr. D.L., et al. Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem Biophys Res Commun 266 (1999) 174-178
73. Lu Y., Zou C.J., Huang D.W., and Tang C.S. Cardiovascular effects of urotensin II in different brain areas. Peptides 23 (2002) 1631-1635
74. MacLean M.R., Alexander D., Stirrat A., Gallagher M., Douglas S.A., Ohlstein E.H., et al. Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol 130 (2000) 201-204
75. Maguire J.J., Kuc R.E., and Davenport A.P. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 131 (2000) 441-446
76. Maguire J.J., Kuc R.E., Wiley K.E., Kleinz M.J., and Davenport A.P. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides 25 (2004) 1767-1774
77. Mallamaci F., Cutrupi S., Pizzini P., Tripepi G., and Zoccali C. Urotensin II and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease. Am J Hypertens 19 (2006) 505-510
78. Mallamaci F., Cutrupi S., Pizzini P., Tripepi G., and Zoccali C. Urotensin II in end-stage renal disease: an inverse correlate of sympathetic function and cardiac natriuretic peptides. J Nephrol 18 (2005) 727-732
79. Marchese A., Heiber M., Nguyen T., Heng H.H., Saldivia V.R., Cheng R., et al. Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors. Genomics 29 (1995) 335-344
80. Marsault R., Feolde E., and Frelin C. Receptor externalization determines sustained contractile responses to endothelin-1 in the rat aorta. Am J Physiol 264 (1993) C687-C693
81. Matsushita M., Shichiri M., Fukai N., Ozawa N., Yoshimoto T., Takasu N., et al. Urotensin II is an autocrine/paracrine growth factor for the porcine renal epithelial cell line, LLCPK1. Endocrinology 144 (2003) 1825-1831
82. Matsushita M., Shichiri M., Imai T., Iwashina M., Tanaka H., Takasu N., et al. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 19 (2001) 2185-2190
83. McMaster D., Kobayashi Y., Rivier J., and Lederis K. Characterization of the biologically and antigenically important regions of urotensin II. Proc West Pharmacol Soc 29 (1986) 205-208
84. Medakovic M., Chan D.K., and Lederis K. Pharmacological effects of urotensins. I. Regional vascular effects of urotensins I and II in the rat. Pharmacology 13 (1975) 409-418
85. Ng L.L., Loke I., O'Brien R.J., Squire I.B., and Davies J.E. Plasma urotensin in human systolic heart failure. Circulation 106 (2002) 2877-2880
86. Ohsako S., Ishida I., Ichikawa T., and Deguchi T. Cloning and sequence analysis of cDNAs encoding precursors of urotensin II-alpha and -gamma. J Neurosci 6 (1986) 2730-2735
87. Ong K.L., Wong L.Y., Man Y.B., Leung R.Y., Song Y.Q., Lam K.S., et al. Haplotypes in the urotensin II gene and urotensin II receptor gene are associated with insulin resistance and impaired glucose tolerance. Peptides 27 (2006) 1659-1667
88. Paysant J., Rupin A., Simonet S., Fabiani J.N., and Verbeuren T.J. Comparison of the contractile responses of human coronary bypass grafts and monkey arteries to human urotensin-II. Fundam Clin Pharmacol 15 (2001) 227-231
89. Pearson D., Shively J.E., Clark B.R., Geschwind I.I., Barkley M., Nishioka R.S., et al. Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci USA 77 (1980) 5021-5024
90. Pelletier G., Lihrmann I., Dubessy C., Luu-The V., Vaudry H., and Labrie F. Androgenic down-regulation of urotensin II precursor, urotensin II-related peptide precursor and androgen receptor mRNA in the mouse spinal cord. Neuroscience 132 (2005) 689-696
91. Pelletier G., Lihrmann I., and Vaudry H. Role of androgens in the regulation of urotensin II precursor mRNA expression in the rat brainstem and spinal cord. Neuroscience 115 (2002) 525-532
92. Pitcher J.A., Freedman N.J., and Lefkowitz R.J. G protein-coupled receptor kinases. Annu Rev Biochem 67 (1998) 653-692
93. Proulx C.D., Simaan M., Escher E., Laporte S.A., Guillemette G., and Leduc R. Involvement of a cytoplasmic-tail serine cluster in urotensin II receptor internalisation. Biochem J 385 (2005) 115-123
94. Qi J., Du J., Tang X., Li J., Wei B., and Tang C. The upregulation of endothelial nitric oxide synthase and urotensin-II is associated with pulmonary hypertension and vascular diseases in rats produced by aortocaval shunting. Heart Vessels 19 (2004) 81-88
95. Qi J.S., Minor L.K., Smith C., Hu B., Yang J., Andrade-Gordon P., et al. Characterization of functional urotensin II receptors in human skeletal muscle myoblasts: comparison with angiotensin II receptors. Peptides 26 (2005) 683-690
96. Richards A.M., Nicholls M.G., Lainchbury J.G., Fisher S., and Yandle T.G. Plasma urotensin II in heart failure. Lancet 360 (2002) 545-546
97. Rossowski W.J., Cheng B.L., Taylor J.E., Datta R., and Coy D.H. Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists. Eur J Pharmacol 438 (2002) 159-170
98. Russell F.D., Kearns P., Toth I., and Molenaar P. Urotensin-II-converting enzyme activity of furin and trypsin in human cells in vitro. J Pharmacol Exp Ther 310 (2004) 209-214
99. Russell F.D., Meyers D., Galbraith A.J., Bett N., Toth I., Kearns P., et al. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 285 (2003) H1576-H1581
100. Russell F.D., and Molenaar P. Investigation of signaling pathways that mediate the inotropic effect of urotensin-II in human heart. Cardiovasc Res 63 (2004) 673-681
101. Russell F.D., Molenaar P., and O'Brien D.M. Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol 132 (2001) 5-9
102. Saetrum Opgaard O., Nothacker H., Ehlert F.J., and Krause D.N. Human urotensin II mediates vasoconstriction via an increase in inositol phosphates. Eur J Pharmacol 406 (2000) 265-271
103. Sauzeau V., Le Mellionnec E., Bertoglio J., Scalbert E., Pacaud P., and Loirand G. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 88 (2001) 1102-1104
104. Schluter H., Jankowski J., Rykl J., Thiemann J., Belgardt S., Zidek W., et al. Detection of protease activities with the mass-spectrometry-assisted enzyme-screening (MES) system. Anal Bioanal Chem 377 (2003) 1102-1107
105. Shenouda A., Douglas S.A., Ohlstein E.H., and Giaid A. Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma. J Histochem Cytochem 50 (2002) 885-889
106. Shi L., Ding W., Li D., Wang Z., Jiang H., Zhang J., et al. Proliferation and anti-apoptotic effects of human urotensin II on human endothelial cells. Atherosclerosis 188 (2006) 260-264
107. Sidharta P.N., Wagner F.D., Bohnemeier H., Jungnik A., Halabi A., Krahenbuhl S., et al. Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther 80 (2006) 246-256
108. Silvestre R.A., Rodriguez-Gallardo J., Egido E.M., and Marco J. Inhibition of insulin release by urotensin II-a study on the perfused rat pancreas. Horm Metab Res Hormon- and Stoffwechselforschung 33 (2001) 379-381
109. Simpson C.M., Penny D.J., Stocker C.F., and Shekerdemian L.S. Urotensin II is raised in children with congenital heart disease. Heart 92 (2006) 983-984
110. Sondermeijer B., Kompa A., Komesaroff P., and Krum H. Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension. Am J Hypertens 18 (2005) 1195-1199
111. Song W., McDonald J., Camarda V., Calo G., Guerrini R., Marzola E., et al. Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity. Naunyn Schmiedebergs Arch Pharmacol 373 (2006) 148-157
112. Stirrat A., Gallagher M., Douglas S.A., Ohlstein E.H., Berry C., Kirk A., et al. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol 280 (2001) H925-H928
113. Sugo T., Murakami Y., Shimomura Y., Harada M., Abe M., Ishibashi Y., et al. Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. Biochem Biophys Res Commun 310 (2003) 860-868
114. Suguro T., Watanabe T., Ban Y., Kodate S., Misaki A., Hirano T., et al. Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. Am J Hypertens 20 (2007) 211-217
115. Suzuki S., Wenyi Z., Hirai M., Hinokio Y., Suzuki C., Yamada T., et al. Genetic variations at urotensin II and urotensin II receptor genes and risk of Type 2 diabetes mellitus in Japanese. Peptides 25 (2004) 1803-1808
116. Takahashi K., Totsune K., Kitamuro T., Sone M., Murakami O., and Shibahara S. Three vasoactive peptides, endothelin-1, adrenomedullin and urotensin-II, in human tumour cell lines of different origin: expression and effects on proliferation. Clin Sci (Lond) 103 Suppl 48 (2002) 35S-38S
117. Tasaki K., Hori M., Ozaki H., Karaki H., and Wakabayashi I. Mechanism of human urotensin II-induced contraction in rat aorta. J Pharmacol Sci 94 (2004) 376-383
118. Thompson J.P., Watt P., Sanghavi S., Strupish J.W., and Lambert D.G. A comparison of cerebrospinal fluid and plasma urotensin II concentrations in normotensive and hypertensive patients undergoing urological surgery during spinal anesthesia: a pilot study. Anesth Analg 97 (2003) 1501-1503
119. Totsune K., Takahashi K., Arihara Z., Sone M., Ito S., and Murakami O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci (Lond) 104 (2003) 1-5
120. Totsune K., Takahashi K., Arihara Z., Sone M., Murakami O., Ito S., et al. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides 25 (2004) 1809-1814
121. Totsune K., Takahashi K., Arihara Z., Sone M., Satoh F., Ito S., et al. Role of urotensin II in patients on dialysis. Lancet 358 (2001) 810-811
122. Tzanidis A., Hannan R.D., Thomas W.G., Onan D., Autelitano D.J., See F., et al. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 93 (2003) 246-253
123. Wang Y.X., Ding Y.J., Zhu Y.Z., Shi Y., Yao T., and Zhu Y.C. Role of PKC in the novel synergistic action of urotensin II and angiotensin II and in urotensin II-induced vasoconstriction. Am J Physiol Heart Circ Physiol 292 (2007) H348-H359
124. Watanabe T., Pakala R., Katagiri T., and Benedict C.R. Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation 104 (2001) 16-18
125. Watanabe T., Pakala R., Katagiri T., and Benedict C.R. Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. J Hypertens 19 (2001) 2191-2196
126. Watanabe T., Suguro T., Kanome T., Sakamoto Y., Kodate S., Hagiwara T., et al. Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension 46 (2005) 738-744
127. Watanabe T., Takahashi K., Kanome T., Hongo S., Miyazaki A., Koba S., et al. Human urotensin-II potentiates the mitogenic effect of mildly oxidized low-density lipoprotein on vascular smooth muscle cells: comparison with other vasoactive agents and hydrogen peroxide. Hypertens Res 29 (2006) 821-831
128. Watson A.M., Lambert G.W., Smith K.J., and May C.N. Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension 42 (2003) 373-379
129. Wenyi Z., Suzuki S., Hirai M., Hinokio Y., Tanizawa Y., Matsutani A., et al. Role of urotensin II gene in genetic susceptibility to Type 2 diabetes mellitus in Japanese subjects. Diabetologia 46 (2003) 972-976
130. Wilkinson I.B., Affolter J.T., de Haas S.L., Pellegrini M.P., Boyd J., Winter M.J., et al. High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res 53 (2002) 341-347
131. Yano K., Vaudry H., and Conlon J.M. Spasmogenic actions of frog urotensin II on the bladder and ileum of the frog, Rana catesbeiana. Gen Comp Endocrinol 96 (1994) 412-419
132. Zhang A.Y., Chen Y.F., Zhang D.X., Yi F.X., Qi J., Andrade-Gordon P., et al. Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol 285 (2003) F792-F798
133. Zhu Y.Z., Wang Z.J., Zhu Y.C., Zhang L., Oakley R.M., Chung C.W., et al. Urotensin II causes fatal circulatory collapse in anesthesized monkeys in vivo: a "vasoconstrictor" with a unique hemodynamic profile. Am J Physiol Heart Circ Physiol 286 (2004) H830-H836
134. Ziltener P., Mueller C., Haenig B., Scherz M.W., and Nayler O. Urotensin II mediates ERK1/2 phosphorylation and proliferation in GPR14-transfected cell lines. J Recept Signal Transduct Res 22 (2002) 155-168
135. Zoccali C., Mallamaci F., Benedetto F.A., Tripepi G., Parlongo S., Cataliotti A., et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 12 (2001) 1508-1515
136. Zoccali C., Mallamaci F., Parlongo S., Cutrupi S., Benedetto F.A., Tripepi G., et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 105 (2002) 1354-1359
137. Zoccali C., Mallamaci F., Tripepi G., Benedetto F.A., Parlongo S., Cutrupi S., et al. Prospective study of neuropeptide y as an adverse cardiovascular risk factor in end-stage renal disease. J Am Soc Nephrol 14 (2003) 2611-2617
138. Zoccali C., Mallamaci F., Tripepi G., Cutrupi S., Pizzini P., and Malatino L. Urotensin II is an inverse predictor of incident cardiovascular events in end-stage renal disease. Kidney Int 69 (2006) 1253-1258